Entheon Biomedical Corp. (ENBI.CN)
CAD 0.17
(0.0%)
CAD 0.17
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 13.99 Thousand CAD | 100.39% |
| 2022 | -3.59 Million CAD | 59.79% |
| 2021 | -8.17 Million CAD | -101.94% |
| 2020 | -1.63 Million CAD | -50088.94% |
| 2019 | -8707.00 CAD | 95.67% |
| 2018 | -229.37 Thousand CAD | -11.0% |
| 2017 | -181.1 Thousand CAD | -7147.18% |
| 2016 | -2499.00 CAD | 72.17% |
| 2015 | -8980.00 CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 7506.00 CAD | 0.0% |
| 2024 Q1 | -77.93 Thousand CAD | -100.0% |
| 2024 Q3 | -67.27 Thousand CAD | -961.95% |
| 2023 Q4 | -74.85 Thousand CAD | 19.07% |
| 2023 FY | - CAD | 91.18% |
| 2023 Q1 | -123.21 Thousand CAD | -278.06% |
| 2023 Q3 | -92.48 Thousand CAD | -268.42% |
| 2023 Q2 | -25.1 Thousand CAD | 79.63% |
| 2022 Q4 | 69.19 Thousand CAD | 110.03% |
| 2022 FY | - CAD | 59.79% |
| 2022 Q3 | -689.77 Thousand CAD | 46.47% |
| 2022 Q2 | -1.28 Million CAD | 21.38% |
| 2022 Q1 | -1.63 Million CAD | 30.2% |
| 2021 Q1 | -3.35 Million CAD | -4.64% |
| 2021 Q2 | -1.59 Million CAD | 52.63% |
| 2021 Q3 | -1.52 Million CAD | 4.17% |
| 2021 Q4 | -2.34 Million CAD | -53.96% |
| 2021 FY | - CAD | -101.94% |
| 2020 Q2 | -44.56 Thousand CAD | -24.21% |
| 2020 FY | - CAD | -50088.94% |
| 2020 Q4 | -3.21 Million CAD | -2856.09% |
| 2020 Q3 | -108.61 Thousand CAD | -143.71% |
| 2020 Q1 | -35.88 Thousand CAD | 27.26% |
| 2019 Q4 | -49.32 Thousand CAD | -173.03% |
| 2019 Q3 | -18.06 Thousand CAD | 58.21% |
| 2019 Q2 | -43.22 Thousand CAD | 45.77% |
| 2019 FY | - CAD | 95.67% |
| 2019 Q1 | -79.71 Thousand CAD | -36.04% |
| 2018 Q1 | -60.39 Thousand CAD | 24.59% |
| 2018 FY | - CAD | -11.0% |
| 2018 Q4 | -58.6 Thousand CAD | -60.07% |
| 2018 Q3 | -36.6 Thousand CAD | 33.37% |
| 2018 Q2 | -54.94 Thousand CAD | 9.04% |
| 2017 Q2 | -5030.00 CAD | 0.0% |
| 2017 Q3 | -35.55 Thousand CAD | -606.84% |
| 2017 Q4 | -80.08 Thousand CAD | -125.26% |
| 2017 FY | - CAD | -7147.18% |
| 2016 FY | - CAD | 72.17% |
| 2015 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -4.98 Million CAD | 100.281% |
| Asep Medical Holdings Inc | -8.13 Million CAD | 100.172% |
| BetterLife Pharma Inc. | -3.19 Million CAD | 100.438% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 100.182% |
| ChitogenX Inc. | -2.69 Million CAD | 100.519% |
| Rapid Dose Therapeutics Corp. | -3.02 Million CAD | 100.463% |
| Defence Therapeutics Inc. | -12.67 Million CAD | 100.11% |
| Gemina Laboratories Ltd. | -5.17 Million CAD | 100.27% |
| Glow Lifetech Corp. | -1.26 Million CAD | 101.108% |
| Lexston Life Sciences Corp. | -648.32 Thousand CAD | 102.158% |
| Pharmala Biotech Holdings Inc. | -710.18 Thousand CAD | 101.97% |
| Doseology Sciences Inc. | -319.47 Thousand CAD | 104.38% |
| MYND Life Sciences Inc. | -1.82 Million CAD | 100.767% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | 101.164% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | 100.46% |
| PreveCeutical Medical Inc. | -955.08 Thousand CAD | 101.465% |
| Telescope Innovations Corp. | -5.49 Million CAD | 100.255% |